chicagoest - I used a $40 billion annual global market for COVID therapies, 10 lead drugs with equal sales, ABL being one of the 10, $4.50 per capsual twice a day for 28 days. That would give RVX $3 to $4 billion in annual sales if the $40 billion annual global sales was the correct starting point.

At $4 billion in annual sales and 1X's sales with 300,000,000 shares out fully diluted, for COVID only it would support US$12 to $13 per share.

Changing market share and pricing will give you the variables for your matrix. Also add in whatever value you give the cardio program knowing that there is a BTD outstanding and the outlook for the share price could look pretty good.

If ABL was able to perform as DM was suggesting on the radio program that was posted at 10:26am this morning then it would not be out of line to expect greater than even sales. There is lots of if's in there, have fun with the numbers.

All IMO, DYODD

tada